ムスカリン性アセチルコリン受容体M2治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0438
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Muscarinic Acetylcholine Receptor M2 – Pipeline Review, H2 2019
Summary

According to the recently published report ‘Muscarinic Acetylcholine Receptor M2 – Pipeline Review, H2 2019′; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 8 molecules.

Muscarinic Acetylcholine Receptor M2 (CHRM2) – Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report ‘Muscarinic Acetylcholine Receptor M2 – Pipeline Review, H2 2019′ outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Respiratory which include indications Alzheimer’s Disease, Overactive Bladder, Depression, Parkinson’s Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Axillary Hyperhidrosis, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Obstructive Sleep Apnea, Pain, Rett Syndrome, Schizophrenia, Stroke, Tuberous Sclerosis and Urinary Incontinence.

Scope

- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
- The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Overview
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
Apnimed Inc
Dare Bioscience Inc
Dermavant Sciences Inc
FemmePharma Global Healthcare Inc
Karuna Therapeutics Inc
TheraVida Inc
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Drug Profiles
(atomoxetine + oxybutynin) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(oxybutynin + pilocarpine) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(pilocarpine + tolterodine) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-141 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blarcamesine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Dormant Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Discontinued Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) – Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: Anavex Life Sciences presents ANAVEX2-73 (blarcamesine) data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 conference
Nov 19, 2019: Karuna Therapeutics’ schizophrenia drug passes Phase II trial
Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
Nov 17, 2019: Karuna Therapeutics schedules webcast and conference call to announce results from its phase 2 clinical trial of KarXT for the treatment of Psychosis in patients with Schizophrenia
Nov 14, 2019: Anavex Life Sciences receives Rare Pediatric Disease Designation from FDA for ANAVEX2-73 (blarcamesine) for the treatment of Rett Syndrome
Nov 06, 2019: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in Rett Syndrome
Oct 10, 2019: Anavex initiates ANAVEX 2-73 study in Alzheimer disease
Oct 02, 2019: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX2-73 for the Treatment of Alzheimer’s Disease
Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study
Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome
Sep 04, 2019: Anavex Life Sciences announces initiation of the EXCELLENCE ANAVEX 2-73-RS-003 clinical study in pediatric patients with Rett Syndrome
Jul 31, 2019: Anavex Life Sciences reports recent data review by the independent data safety monitoring board for its US phase 2 clinical trial of ANAVEX 2-73 in patients with Rett syndrome
Jul 29, 2019: Anavex Life Sciences receives positive opinion for orphan designation from the European Medicines Agency for ANAVEX2-73 for the treatment of rett syndrome
Jul 17, 2019: Anavex Life Sciences presents new clinical data identifying gut microbiota biomarkers asociated with improved clinical response in patients treated with ANAVEX2-73 at 2019 Alzheimer’s Association International Conference (AAIC)
Jun 25, 2019: Anavex Life Sciences announces first patient dosed in extension study to its U.S. phase 2 clinical trial of ANAVEX2-73 in patients for Rett Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Anavex Life Sciences Corp, H2 2019
Pipeline by Apnimed Inc, H2 2019
Pipeline by Dare Bioscience Inc, H2 2019
Pipeline by Dermavant Sciences Inc, H2 2019
Pipeline by FemmePharma Global Healthcare Inc, H2 2019
Pipeline by Karuna Therapeutics Inc, H2 2019
Pipeline by TheraVida Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Anavex Life Sciences Corp
Apnimed Inc
Dare Bioscience Inc
Dermavant Sciences Inc
FemmePharma Global Healthcare Inc
Karuna Therapeutics Inc
TheraVida Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ムスカリン性アセチルコリン受容体M2治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆